Fulton Breakefield Broenniman LLC lessened its holdings in Clorox Co (NYSE:CLX) by 1.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 85,161 shares of the company’s stock after selling 900 shares during the quarter. Clorox accounts for 2.0% of Fulton Breakefield Broenniman LLC’s investment portfolio, making the stock its 18th biggest position. Fulton Breakefield Broenniman LLC owned 0.07% of Clorox worth $17,898,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Altium Wealth Management LLC grew its holdings in Clorox by 1.7% in the 2nd quarter. Altium Wealth Management LLC now owns 2,735 shares of the company’s stock worth $600,000 after acquiring an additional 47 shares during the last quarter. CNB Bank raised its holdings in Clorox by 1.2% in the second quarter. CNB Bank now owns 4,150 shares of the company’s stock worth $910,000 after buying an additional 50 shares during the last quarter. Peoples Bank OH raised its holdings in Clorox by 1.5% in the second quarter. Peoples Bank OH now owns 3,415 shares of the company’s stock worth $749,000 after buying an additional 50 shares during the last quarter. GYL Financial Synergies LLC raised its holdings in Clorox by 4.1% in the second quarter. GYL Financial Synergies LLC now owns 1,271 shares of the company’s stock worth $279,000 after buying an additional 50 shares during the last quarter. Finally, Meeder Asset Management Inc. raised its holdings in Clorox by 7.8% in the first quarter. Meeder Asset Management Inc. now owns 702 shares of the company’s stock worth $122,000 after buying an additional 51 shares during the last quarter. Institutional investors own 79.18% of the company’s stock.
CLX has been the subject of several recent analyst reports. Credit Suisse Group lifted their target price on shares of Clorox from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Zacks Investment Research cut shares of Clorox from a “buy” rating to a “hold” rating and set a $249.00 price objective for the company. in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Clorox from $174.00 to $223.00 and gave the company a “hold” rating in a report on Monday, July 27th. JPMorgan Chase & Co. cut shares of Clorox from an “overweight” rating to a “neutral” rating and set a $235.00 price objective for the company. in a report on Friday, October 16th. They noted that the move was a valuation call. Finally, DA Davidson decreased their price objective on shares of Clorox from $269.00 to $263.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $210.42.
Clorox (NYSE:CLX) last posted its quarterly earnings results on Monday, August 3rd. The company reported $2.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.41. The business had revenue of $1.98 billion during the quarter, compared to analyst estimates of $1.86 billion. Clorox had a net margin of 13.97% and a return on equity of 138.70%. The company’s revenue was up 21.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.88 earnings per share. Sell-side analysts predict that Clorox Co will post 7.71 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, November 20th. Shareholders of record on Wednesday, November 4th will be given a $1.11 dividend. The ex-dividend date is Tuesday, November 3rd. This represents a $4.44 dividend on an annualized basis and a dividend yield of 2.10%. Clorox’s payout ratio is currently 60.33%.
In related news, SVP Andrew J. Mowery sold 12,932 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $235.97, for a total transaction of $3,051,564.04. Following the completion of the transaction, the senior vice president now owns 18,456 shares in the company, valued at $4,355,062.32. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Diego J. Barral sold 10,041 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $235.59, for a total transaction of $2,365,559.19. Following the transaction, the senior vice president now owns 13,931 shares of the company’s stock, valued at approximately $3,282,004.29. The disclosure for this sale can be found here. Corporate insiders own 1.09% of the company’s stock.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Scentiva, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; professional cleaning, disinfecting, and food service products under the CloroxPro, Clorox Healthcare, and Clorox Total 360 brands; professional food service products under the Hidden Valley brand; and vitamins, minerals, and supplement products under the RenewLife, Rainbow Light, Natural Vitality, NeoCell, and Stop Aging Now brands.
Read More: Google Finance Portfolio Tips and Tricks
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co (NYSE:CLX).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.